Lung function impairment, COPD hospitalisations and subsequent mortality

BackgroundHospitalisations and their sequelae comprise key morbidities in the natural history of chronic obstructive pulmonary disease (COPD). A study was undertaken to examine the associations between lung function impairment and COPD hospitalisation, and COPD hospitalisation and mortality.MethodsT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax 2011-07, Vol.66 (7), p.585-590
Hauptverfasser: Garcia-Aymerich, Judith, Serra Pons, Ignasi, Mannino, David M, Maas, Andrea K, Miller, David P, Davis, Kourtney J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 590
container_issue 7
container_start_page 585
container_title Thorax
container_volume 66
creator Garcia-Aymerich, Judith
Serra Pons, Ignasi
Mannino, David M
Maas, Andrea K
Miller, David P
Davis, Kourtney J
description BackgroundHospitalisations and their sequelae comprise key morbidities in the natural history of chronic obstructive pulmonary disease (COPD). A study was undertaken to examine the associations between lung function impairment and COPD hospitalisation, and COPD hospitalisation and mortality.MethodsThe analysis included a population-based sample of 20 571 participants with complete demographic, lung function, smoking, hospitalisation and mortality data, with 10-year median follow-up. Participants were classified by prebronchodilator lung function according to the modified Global Initiative on Obstructive Lung Disease (GOLD) criteria. Hospitalisations were defined by the presence of a COPD discharge diagnosis (ICD-9 codes 490–496). Incidence rate ratios (IRR) of COPD admissions and hazard ratios (HR) of mortality with respective 95% CI were calculated, adjusted for potential confounders.ResultsThe prevalence of modified GOLD categories was normal (36%), restricted (15%), GOLD stage 0 (22%), GOLD stage 1 (13%), GOLD stage 2 (11%) and GOLD stages 3 or 4 (3%). Adjusted IRRs (and 95% CI) indicated an increased risk of COPD hospitalisation associated with each COPD stage relative to normal lung function: 4.7 (3.7 to 6.1), 2.1 (1.6 to 2.6), 3.2 (2.6 to 4.0), 8.0 (6.4 to 10.0) and 25.5 (19.5 to 33.4) for the restricted, GOLD stage 0, GOLD stage 1, GOLD stage 2 and GOLD stages 3 or 4, respectively. Hospitalisation for COPD increased the risk of subsequent mortality (HR 2.7, 95% CI 2.5 to 3.0), controlling for severity, number of prior hospitalisations and other potential confounders. The increase in mortality associated with admission was very similar across the modified GOLD stages.ConclusionsCOPD severity was associated with a higher rate of severe exacerbations requiring hospitalisation, although severe exacerbations at any stage were associated with a higher risk of short-term and long-term all-cause mortality.
doi_str_mv 10.1136/thx.2010.152876
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_872437874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>872437874</sourcerecordid><originalsourceid>FETCH-LOGICAL-b534t-6a573a3a98893ec526b9c57d3d151b89c8c444a4489615b54d0124a684cf1f8f3</originalsourceid><addsrcrecordid>eNqF0Etr3DAUBWBRWpLJY91dMZQQKPVEsq4eXpZJMhMYMoEk3QpZlhtN_ZhKNiT_PjKeptBNVkLc714OB6HPBM8Jofyif3qeZ3j8sUwK_gHNCHCZ0iznH9EMY8App4IfoqMQthhjSYg4QIcZYYQxRmdotR7aX0k1tKZ3XZu4Zqedb2zbf08Wm7vL5KkLO9fr2gU9gpDotkzCUAT7Z4gqaTo_TvuXE_Sp0nWwp_v3GD1eXz0sVul6s7xZ_FinBaPQp1wzQTXVuZQ5tYZlvMgNEyUtY6RC5kYaANAAMueEFQxKTDLQXIKpSCUreozOp7s738UIoVeNC8bWtW5tNwQlRQZUSAFRfv1PbrvBtzGcIkISmXGQIqqLSRnfheBtpXbeNdq_KILV2LGKHauxYzV1HDe-7O8ORWPLN_-31AjO9kAHo-vK69a48M8BxQIgjy6dnAu9fX6ba_9bcUEFU7c_F2oF6_vlLcvVMvpvky-a7bspXwGqCZ9U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781826487</pqid></control><display><type>article</type><title>Lung function impairment, COPD hospitalisations and subsequent mortality</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>Alma/SFX Local Collection</source><creator>Garcia-Aymerich, Judith ; Serra Pons, Ignasi ; Mannino, David M ; Maas, Andrea K ; Miller, David P ; Davis, Kourtney J</creator><creatorcontrib>Garcia-Aymerich, Judith ; Serra Pons, Ignasi ; Mannino, David M ; Maas, Andrea K ; Miller, David P ; Davis, Kourtney J</creatorcontrib><description>BackgroundHospitalisations and their sequelae comprise key morbidities in the natural history of chronic obstructive pulmonary disease (COPD). A study was undertaken to examine the associations between lung function impairment and COPD hospitalisation, and COPD hospitalisation and mortality.MethodsThe analysis included a population-based sample of 20 571 participants with complete demographic, lung function, smoking, hospitalisation and mortality data, with 10-year median follow-up. Participants were classified by prebronchodilator lung function according to the modified Global Initiative on Obstructive Lung Disease (GOLD) criteria. Hospitalisations were defined by the presence of a COPD discharge diagnosis (ICD-9 codes 490–496). Incidence rate ratios (IRR) of COPD admissions and hazard ratios (HR) of mortality with respective 95% CI were calculated, adjusted for potential confounders.ResultsThe prevalence of modified GOLD categories was normal (36%), restricted (15%), GOLD stage 0 (22%), GOLD stage 1 (13%), GOLD stage 2 (11%) and GOLD stages 3 or 4 (3%). Adjusted IRRs (and 95% CI) indicated an increased risk of COPD hospitalisation associated with each COPD stage relative to normal lung function: 4.7 (3.7 to 6.1), 2.1 (1.6 to 2.6), 3.2 (2.6 to 4.0), 8.0 (6.4 to 10.0) and 25.5 (19.5 to 33.4) for the restricted, GOLD stage 0, GOLD stage 1, GOLD stage 2 and GOLD stages 3 or 4, respectively. Hospitalisation for COPD increased the risk of subsequent mortality (HR 2.7, 95% CI 2.5 to 3.0), controlling for severity, number of prior hospitalisations and other potential confounders. The increase in mortality associated with admission was very similar across the modified GOLD stages.ConclusionsCOPD severity was associated with a higher rate of severe exacerbations requiring hospitalisation, although severe exacerbations at any stage were associated with a higher risk of short-term and long-term all-cause mortality.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thx.2010.152876</identifier><identifier>PMID: 21515553</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Age Distribution ; Aged ; Aged, 80 and over ; Atherosclerosis ; Biological and medical sciences ; Body mass index ; Cardiology. Vascular system ; Cardiovascular disease ; chronic obstructive ; Chronic obstructive pulmonary disease ; Chronic obstructive pulmonary disease, asthma ; clinical epidemiology ; COPD epidemiology ; COPD exacerbation ; Diabetes ; Epidemiologic Methods ; epidemiology ; Exercise ; Female ; Forced Expiratory Volume - physiology ; hospitalisation ; Hospitalization - statistics &amp; numerical data ; Hospitals ; Humans ; Lung - physiopathology ; Lung diseases ; Male ; Medical sciences ; Middle Aged ; Mortality ; Pneumology ; Population ; Prognosis ; Pulmonary disease ; Pulmonary Disease, Chronic Obstructive - mortality ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Questionnaires ; Sex Distribution ; Spirometry - methods ; United States - epidemiology ; Vital Capacity - physiology</subject><ispartof>Thorax, 2011-07, Vol.66 (7), p.585-590</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b534t-6a573a3a98893ec526b9c57d3d151b89c8c444a4489615b54d0124a684cf1f8f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://thorax.bmj.com/content/66/7/585.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://thorax.bmj.com/content/66/7/585.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24307449$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21515553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcia-Aymerich, Judith</creatorcontrib><creatorcontrib>Serra Pons, Ignasi</creatorcontrib><creatorcontrib>Mannino, David M</creatorcontrib><creatorcontrib>Maas, Andrea K</creatorcontrib><creatorcontrib>Miller, David P</creatorcontrib><creatorcontrib>Davis, Kourtney J</creatorcontrib><title>Lung function impairment, COPD hospitalisations and subsequent mortality</title><title>Thorax</title><addtitle>Thorax</addtitle><description>BackgroundHospitalisations and their sequelae comprise key morbidities in the natural history of chronic obstructive pulmonary disease (COPD). A study was undertaken to examine the associations between lung function impairment and COPD hospitalisation, and COPD hospitalisation and mortality.MethodsThe analysis included a population-based sample of 20 571 participants with complete demographic, lung function, smoking, hospitalisation and mortality data, with 10-year median follow-up. Participants were classified by prebronchodilator lung function according to the modified Global Initiative on Obstructive Lung Disease (GOLD) criteria. Hospitalisations were defined by the presence of a COPD discharge diagnosis (ICD-9 codes 490–496). Incidence rate ratios (IRR) of COPD admissions and hazard ratios (HR) of mortality with respective 95% CI were calculated, adjusted for potential confounders.ResultsThe prevalence of modified GOLD categories was normal (36%), restricted (15%), GOLD stage 0 (22%), GOLD stage 1 (13%), GOLD stage 2 (11%) and GOLD stages 3 or 4 (3%). Adjusted IRRs (and 95% CI) indicated an increased risk of COPD hospitalisation associated with each COPD stage relative to normal lung function: 4.7 (3.7 to 6.1), 2.1 (1.6 to 2.6), 3.2 (2.6 to 4.0), 8.0 (6.4 to 10.0) and 25.5 (19.5 to 33.4) for the restricted, GOLD stage 0, GOLD stage 1, GOLD stage 2 and GOLD stages 3 or 4, respectively. Hospitalisation for COPD increased the risk of subsequent mortality (HR 2.7, 95% CI 2.5 to 3.0), controlling for severity, number of prior hospitalisations and other potential confounders. The increase in mortality associated with admission was very similar across the modified GOLD stages.ConclusionsCOPD severity was associated with a higher rate of severe exacerbations requiring hospitalisation, although severe exacerbations at any stage were associated with a higher risk of short-term and long-term all-cause mortality.</description><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atherosclerosis</subject><subject>Biological and medical sciences</subject><subject>Body mass index</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>chronic obstructive</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>clinical epidemiology</subject><subject>COPD epidemiology</subject><subject>COPD exacerbation</subject><subject>Diabetes</subject><subject>Epidemiologic Methods</subject><subject>epidemiology</subject><subject>Exercise</subject><subject>Female</subject><subject>Forced Expiratory Volume - physiology</subject><subject>hospitalisation</subject><subject>Hospitalization - statistics &amp; numerical data</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lung - physiopathology</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Pneumology</subject><subject>Population</subject><subject>Prognosis</subject><subject>Pulmonary disease</subject><subject>Pulmonary Disease, Chronic Obstructive - mortality</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Questionnaires</subject><subject>Sex Distribution</subject><subject>Spirometry - methods</subject><subject>United States - epidemiology</subject><subject>Vital Capacity - physiology</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0Etr3DAUBWBRWpLJY91dMZQQKPVEsq4eXpZJMhMYMoEk3QpZlhtN_ZhKNiT_PjKeptBNVkLc714OB6HPBM8Jofyif3qeZ3j8sUwK_gHNCHCZ0iznH9EMY8App4IfoqMQthhjSYg4QIcZYYQxRmdotR7aX0k1tKZ3XZu4Zqedb2zbf08Wm7vL5KkLO9fr2gU9gpDotkzCUAT7Z4gqaTo_TvuXE_Sp0nWwp_v3GD1eXz0sVul6s7xZ_FinBaPQp1wzQTXVuZQ5tYZlvMgNEyUtY6RC5kYaANAAMueEFQxKTDLQXIKpSCUreozOp7s738UIoVeNC8bWtW5tNwQlRQZUSAFRfv1PbrvBtzGcIkISmXGQIqqLSRnfheBtpXbeNdq_KILV2LGKHauxYzV1HDe-7O8ORWPLN_-31AjO9kAHo-vK69a48M8BxQIgjy6dnAu9fX6ba_9bcUEFU7c_F2oF6_vlLcvVMvpvky-a7bspXwGqCZ9U</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Garcia-Aymerich, Judith</creator><creator>Serra Pons, Ignasi</creator><creator>Mannino, David M</creator><creator>Maas, Andrea K</creator><creator>Miller, David P</creator><creator>Davis, Kourtney J</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Lung function impairment, COPD hospitalisations and subsequent mortality</title><author>Garcia-Aymerich, Judith ; Serra Pons, Ignasi ; Mannino, David M ; Maas, Andrea K ; Miller, David P ; Davis, Kourtney J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b534t-6a573a3a98893ec526b9c57d3d151b89c8c444a4489615b54d0124a684cf1f8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atherosclerosis</topic><topic>Biological and medical sciences</topic><topic>Body mass index</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>chronic obstructive</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>clinical epidemiology</topic><topic>COPD epidemiology</topic><topic>COPD exacerbation</topic><topic>Diabetes</topic><topic>Epidemiologic Methods</topic><topic>epidemiology</topic><topic>Exercise</topic><topic>Female</topic><topic>Forced Expiratory Volume - physiology</topic><topic>hospitalisation</topic><topic>Hospitalization - statistics &amp; numerical data</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lung - physiopathology</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Pneumology</topic><topic>Population</topic><topic>Prognosis</topic><topic>Pulmonary disease</topic><topic>Pulmonary Disease, Chronic Obstructive - mortality</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Questionnaires</topic><topic>Sex Distribution</topic><topic>Spirometry - methods</topic><topic>United States - epidemiology</topic><topic>Vital Capacity - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia-Aymerich, Judith</creatorcontrib><creatorcontrib>Serra Pons, Ignasi</creatorcontrib><creatorcontrib>Mannino, David M</creatorcontrib><creatorcontrib>Maas, Andrea K</creatorcontrib><creatorcontrib>Miller, David P</creatorcontrib><creatorcontrib>Davis, Kourtney J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia-Aymerich, Judith</au><au>Serra Pons, Ignasi</au><au>Mannino, David M</au><au>Maas, Andrea K</au><au>Miller, David P</au><au>Davis, Kourtney J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lung function impairment, COPD hospitalisations and subsequent mortality</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>66</volume><issue>7</issue><spage>585</spage><epage>590</epage><pages>585-590</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>BackgroundHospitalisations and their sequelae comprise key morbidities in the natural history of chronic obstructive pulmonary disease (COPD). A study was undertaken to examine the associations between lung function impairment and COPD hospitalisation, and COPD hospitalisation and mortality.MethodsThe analysis included a population-based sample of 20 571 participants with complete demographic, lung function, smoking, hospitalisation and mortality data, with 10-year median follow-up. Participants were classified by prebronchodilator lung function according to the modified Global Initiative on Obstructive Lung Disease (GOLD) criteria. Hospitalisations were defined by the presence of a COPD discharge diagnosis (ICD-9 codes 490–496). Incidence rate ratios (IRR) of COPD admissions and hazard ratios (HR) of mortality with respective 95% CI were calculated, adjusted for potential confounders.ResultsThe prevalence of modified GOLD categories was normal (36%), restricted (15%), GOLD stage 0 (22%), GOLD stage 1 (13%), GOLD stage 2 (11%) and GOLD stages 3 or 4 (3%). Adjusted IRRs (and 95% CI) indicated an increased risk of COPD hospitalisation associated with each COPD stage relative to normal lung function: 4.7 (3.7 to 6.1), 2.1 (1.6 to 2.6), 3.2 (2.6 to 4.0), 8.0 (6.4 to 10.0) and 25.5 (19.5 to 33.4) for the restricted, GOLD stage 0, GOLD stage 1, GOLD stage 2 and GOLD stages 3 or 4, respectively. Hospitalisation for COPD increased the risk of subsequent mortality (HR 2.7, 95% CI 2.5 to 3.0), controlling for severity, number of prior hospitalisations and other potential confounders. The increase in mortality associated with admission was very similar across the modified GOLD stages.ConclusionsCOPD severity was associated with a higher rate of severe exacerbations requiring hospitalisation, although severe exacerbations at any stage were associated with a higher risk of short-term and long-term all-cause mortality.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><pmid>21515553</pmid><doi>10.1136/thx.2010.152876</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0040-6376
ispartof Thorax, 2011-07, Vol.66 (7), p.585-590
issn 0040-6376
1468-3296
language eng
recordid cdi_proquest_miscellaneous_872437874
source MEDLINE; BMJ Journals - NESLi2; Alma/SFX Local Collection
subjects Age Distribution
Aged
Aged, 80 and over
Atherosclerosis
Biological and medical sciences
Body mass index
Cardiology. Vascular system
Cardiovascular disease
chronic obstructive
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease, asthma
clinical epidemiology
COPD epidemiology
COPD exacerbation
Diabetes
Epidemiologic Methods
epidemiology
Exercise
Female
Forced Expiratory Volume - physiology
hospitalisation
Hospitalization - statistics & numerical data
Hospitals
Humans
Lung - physiopathology
Lung diseases
Male
Medical sciences
Middle Aged
Mortality
Pneumology
Population
Prognosis
Pulmonary disease
Pulmonary Disease, Chronic Obstructive - mortality
Pulmonary Disease, Chronic Obstructive - physiopathology
Questionnaires
Sex Distribution
Spirometry - methods
United States - epidemiology
Vital Capacity - physiology
title Lung function impairment, COPD hospitalisations and subsequent mortality
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A08%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lung%20function%20impairment,%20COPD%20hospitalisations%20and%20subsequent%20mortality&rft.jtitle=Thorax&rft.au=Garcia-Aymerich,%20Judith&rft.date=2011-07-01&rft.volume=66&rft.issue=7&rft.spage=585&rft.epage=590&rft.pages=585-590&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thx.2010.152876&rft_dat=%3Cproquest_cross%3E872437874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781826487&rft_id=info:pmid/21515553&rfr_iscdi=true